Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950646937> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- W2950646937 abstract "e15159 Background: Carcinoma of the advanced cervical esophagus is a highly virulent disease. Although surgery is considered the standard therapy, the results of surgery alone remain poor. The present study analyzes the efficacy of concurrent chemoradiotherapy (CCRT) with S-1 and cisplatin for advanced cervical esophageal carcinoma (ACEC). Methods: CCRT comprised two courses, 30-Gy radiotherapy over 3 weeks (2 Gy per fraction, 5 times a week) accompanied by daily oral S-1 powder (80 mg/m 2 /day) for 2 weeks and a 24-hr cisplatin infusion (70 mg/m 2 ) on Day 8. An identical course was administered after a 2-week break. Responders received a 5-week cycle of chemotherapy with S-1 and cisplatin. Results: Twenty-one subjects, 3 with Stage II, 14 with Stage III, and 4 with Stage IV ACEC participated, and all completed the CCRT courses. Eighteen subjects received a total of 59 cycles of chemotherapy after CCRT and a median of 3 cycles per subject was administered (range: 1 to 9 cycles). Complete response rates in subjects with Stage II, Stage III, and Stage IV diseases were 100%, 85.7%, and 25%, respectively, and a dysphagia-free status was found in 80.9%. The most serious toxicity was myelosuppression; Grades 3 and 4 neutropenia occurred in 33.3% and 9.5%, of subjects, respectively. Non-hematologic toxicities were moderate. The most common were Grade 2 nausea (38.0%), esophageal pain, and oral mucositis (19.0% each) and renal dysfunction (9.5%). Adverse events from the first course of CCRT resolved during the 2-week treatment break. Overall median progression-free survival was 1.5 years and the median survival time was 2.5 years. The 1- and 5-year survival rates were 75.0 and 27.7%, respectively. Conclusions: This regimen showed favorable antitumor activity, improving survival and quality of life with tolerable toxicity, and could become an alternative to conventional surgery for the treatment of ACEC." @default.
- W2950646937 created "2019-06-27" @default.
- W2950646937 creator A5004453528 @default.
- W2950646937 creator A5006244440 @default.
- W2950646937 creator A5010121166 @default.
- W2950646937 creator A5017943831 @default.
- W2950646937 creator A5019040812 @default.
- W2950646937 creator A5032676273 @default.
- W2950646937 creator A5049263936 @default.
- W2950646937 creator A5051081858 @default.
- W2950646937 creator A5076465734 @default.
- W2950646937 creator A5088628789 @default.
- W2950646937 date "2013-05-20" @default.
- W2950646937 modified "2023-09-27" @default.
- W2950646937 title "Concurrent chemoradiotherapy with S-1 plus cisplatin for advanced cervical esophageal carcinoma: Long-term results of a phase II trial." @default.
- W2950646937 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.e15159" @default.
- W2950646937 hasPublicationYear "2013" @default.
- W2950646937 type Work @default.
- W2950646937 sameAs 2950646937 @default.
- W2950646937 citedByCount "0" @default.
- W2950646937 crossrefType "journal-article" @default.
- W2950646937 hasAuthorship W2950646937A5004453528 @default.
- W2950646937 hasAuthorship W2950646937A5006244440 @default.
- W2950646937 hasAuthorship W2950646937A5010121166 @default.
- W2950646937 hasAuthorship W2950646937A5017943831 @default.
- W2950646937 hasAuthorship W2950646937A5019040812 @default.
- W2950646937 hasAuthorship W2950646937A5032676273 @default.
- W2950646937 hasAuthorship W2950646937A5049263936 @default.
- W2950646937 hasAuthorship W2950646937A5051081858 @default.
- W2950646937 hasAuthorship W2950646937A5076465734 @default.
- W2950646937 hasAuthorship W2950646937A5088628789 @default.
- W2950646937 hasConcept C121608353 @default.
- W2950646937 hasConcept C126322002 @default.
- W2950646937 hasConcept C143998085 @default.
- W2950646937 hasConcept C2776694085 @default.
- W2950646937 hasConcept C2777546739 @default.
- W2950646937 hasConcept C2778220009 @default.
- W2950646937 hasConcept C2778239845 @default.
- W2950646937 hasConcept C2778424827 @default.
- W2950646937 hasConcept C2993195994 @default.
- W2950646937 hasConcept C31760486 @default.
- W2950646937 hasConcept C71924100 @default.
- W2950646937 hasConceptScore W2950646937C121608353 @default.
- W2950646937 hasConceptScore W2950646937C126322002 @default.
- W2950646937 hasConceptScore W2950646937C143998085 @default.
- W2950646937 hasConceptScore W2950646937C2776694085 @default.
- W2950646937 hasConceptScore W2950646937C2777546739 @default.
- W2950646937 hasConceptScore W2950646937C2778220009 @default.
- W2950646937 hasConceptScore W2950646937C2778239845 @default.
- W2950646937 hasConceptScore W2950646937C2778424827 @default.
- W2950646937 hasConceptScore W2950646937C2993195994 @default.
- W2950646937 hasConceptScore W2950646937C31760486 @default.
- W2950646937 hasConceptScore W2950646937C71924100 @default.
- W2950646937 hasLocation W29506469371 @default.
- W2950646937 hasOpenAccess W2950646937 @default.
- W2950646937 hasPrimaryLocation W29506469371 @default.
- W2950646937 isParatext "false" @default.
- W2950646937 isRetracted "false" @default.
- W2950646937 magId "2950646937" @default.
- W2950646937 workType "article" @default.